Given the multifaceted nature of ADCs, developers should have an integrated analytical toolkit. Three complementary approaches dominate the current landscape: Ligand Binding Assays (LBA): Ideal for ...

We’re in the midst of a paradigm shift in biomarker science. Once considered exploratory, biomarker signatures have evolved into strategic assets - tools that actively de-risk decision-making across ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors, and the general public. Researchers have ...

Artificial intelligence (AI) is fundamentally reshaping the landscape of solid tumor (ST) drug development. By integrating multi-omics data, spatial transcriptomics, and advanced computational models, ...

On January 22, 25, and 27, 2021, the National Academies convened a virtual workshop—sponsored by the Food and Drug Administration—on the challenges and opportunities to improve the evidence base for ...